https://orcid.org/0000-0003-1413-5152
Figures
Abstract
Background
Critically ill patients with cardiogenic shock could benefit from ventricular assist device support using the Impella microaxial blood pump. However, recent studies suggested Impella not to improve outcomes. We, therefore, evaluated outcomes and predictors in a real-world scenario.
Methods
In this retrospective single-center trial, 125 patients suffering from cardiac arrest/cardiogenic shock between 2008 and 2018 were analyzed. 93 Patients had a prior successful cardiopulmonary resuscitation. The primary endpoint was hospital mortality. Associations of covariates with the primary endpoint were assessed by univariable and multivariable logistic regression. Adjusted odds ratios (aOR) and optimal cut-offs (using Youden index) were obtained.
Results
Hospital mortality was high (81%). Baseline lactate was 4.7mmol/L [IQR = 7.1mmol/L]. In multivariable logistic regression, only age (aOR 1.13 95%CI 1.06–1.20; p<0.001) and lactate (aOR 1.23 95%CI 1.004–1.516; p = 0.046) were associated with hospital mortality, and the respective optimal cut-offs were >3.3mmol/L and age >66 years.
Patients were retrospectively stratified into three risk groups: Patients aged ≤66 years and lactate ≤3.3mmol (low-risk; n = 22); patients aged >66 years or lactate >3.3mmol/L (medium-risk; n = 52); and patients both aged >66 years and lactate >3.3mmol/L (high-risk, n = 51). Risk of death increased from 41% in the low-risk group, to 79% in the medium risk group and 100% in the high-risk group. The predictive abilities of this model were high (AUC 0.84; 95% 0.77–0.92).
Citation: Abdullah KQA, Roedler JV, vom Dahl J, Szendey I, Haake H, Eckardt L, et al. (2021) Impella use in real-world cardiogenic shock patients: Sobering outcomes. PLoS ONE 16(2): e0247667. https://doi.org/10.1371/journal.pone.0247667
Editor: Andrea Ballotta, IRCCS Policlinico S.Donato, ITALY
Received: October 10, 2020; Accepted: February 10, 2021; Published: February 26, 2021
Copyright: © 2021 Abdullah et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the manuscript and its Supporting information files.
Funding: We state that the authors received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
1.0 Introduction
1.1 Background
In critically ill patients with cardiogenic shock (CS), ventricular assist devices protect against systemic hypotension and tissue hypofunction and thus could help to improve outcomes. The Impella transvalvular microaxial blood pump (Abiomed, Danvers, USA) is a commonly used assist device in this population for active LV unloading, sometimes combined with VA-ECMO. Impella supports hemodynamic stabilization and provides intermediate support by increasing cardiac output up to 3–5.0 L/min depending on the generation of the assist device. All Impella pumps, except the Impella 5.0 can be inserted percutaneously into the femoral artery and create a non-pulsatile, forward flow into the aorta. Previous studies have shown that Impella improves MAP [1], reduces LV-Load, end-diastolic pressure, oxygen consumption and myocardial work [2]. The ISAR-SHOCK Trial showed that Impella provided numerous hemodynamic improvements including cardiac index, cardiac output, MAP 30 minutes after implantation with reversal of serum lactate values [3].
Importantly, some previous studies have shown improved survival in patients with medical therapy refractory CS [4,5]. However, the mortality in patients with cardiogenic shock with a need for an assist device is high, and the therapy with Impella also bears the potential for sometimes severe complications such as reduced platelet aggregation, mechanical hemolysis, acquired von Willebrand syndrome, high purge pressures, sensor failure, suction episodes, device thrombosis, and aortic or mitral valve injury [1,6]. Other access-related complications include bleeding and vascular complications such as limb ischemia, pseudoaneurysm, and arteriovenous fistula [7]. A very recent, propensity-matched and registry-based, retrospective study by Dhruva et al. showed that the use of a microaxial LVAD in CS due to myocardial infarction had a higher risk of in-hospital death [8]. Other data from a collective of 204 patients with CS showed a strong correlation of lactate and outcome, however, they did not include patients with prior resuscitation [9]. In conclusion, it remains unclear which parameters might be helpful in real-world collectives that include patients with CS and prior successful resuscitation.
We, therefore, analyzed patients with CA/CS treated with Impella at our hospital to describe outcomes and predictors of mortality in a contemporary real-world collective.
2.0 Methods
2.1 Study design and setting
In this retrospective single-center trial, we analyzed 125 consecutive patients (36 female, 69.0±18.0 years) with CA/CS shock that were admitted to our intensive care unit (ICU) from 8/2007-7/2018. Ninety-three patients had prior successful CPR.
2.2 Eligibility
We included patients with cardiac arrest and/or CA/CS as determined by a systolic blood pressure below 90 mmHg for more than 30 minutes, the presence of elevated serum lactate values >2mmol/L or continuous hemodynamic instability despite inotrope or vasopressor therapy that required the implantation of an Impella blood pump. Impella position was routinely checked every 12 h in our ICU using transthoracic echocardiography by a skilled cardiologist and optimized when necessary. CA/CS in our collective was due to myocardial infarction or endstage heart failure in dilatative cardiomyopathy. The source of the medical records, samples, data regarding medication, results from diagnostic tests as well as the history of concomitant diseases was the patient database of Kliniken Maria Hilf GmbH, Mönchengladbach, Germany. The data was stored and organized using the MetaVision Software (iMDsoft, Israel). The primary endpoint of this study was hospital mortality.
2.3 Variables
We assessed the associations of outcome with age, lactate concentrations and CPR duration before Impella implantation.
2.4 Statistical analysis
The statistical analysis was carried out blindly by our statistical analytic team using the SPSS 22 software (IBM Corp, Armonk, NY, USA). Descriptive statistics were obtained for study variables. All categorical variables were compared by using the Fisher exact test. Continuous data are presented as median and interquartile range [IQR] values and variables were compared using the Mann-Whitney U test. Logistic regression was used to evaluate associations with the primary endpoint. Odds ratios (OR) and adjusted odds ratios (aOR) with 95% confidence intervals (CI) were obtained. For a multivariable logistic regression model, confounders with a p-value <0.10 in the univariate analysis were included, then a backward variable elimination was performed.
The discrimination accuracy was evaluated using ROC analysis and the c-index (area-under-the-curve (AUC)) as a cumulative measure. An optimal cut-off was calculated by means of the Youden index. We performed a sensitivity analysis in the patients with previous successful cardiopulmonary reanimation, and with acute myocardial infarction (AMI) as primary underlying pathology for the CS.
All tests were two-sided and P-values <0.05 were considered statistically significant.
2.5 Ethics
The local ethical board of the Aerztekammer Nordrhein Westfalen approved this study (Approval Nr.: 154/2019). The study conformed with the principals outlined in the declaration of Helsinki. All data were fully anonymized befor evaluation. Our Ethics committee waived the requirements for informed consent. The authors received no specific funding for this work.
3.0 Results
3.1 Baseline characteristics in survivors vs. non-survivors
The majority of our patients were male (71.2%, n = 89) and had risk factors for coronary artery disease (CAD, 87.2%, n = 109) such as arterial hypertension (HTN, 60.8%, n = 76) and diabetes mellitus (DM, 25.6%, n = 32). Patients with HFrEF (41.6%, n = 52) and structural heart disease (20.0%, n = 25) were frequent. Median left ventricular ejection fraction was 25% [25%] as assessed by echocardiography using eyeballing and the biplane Simpson method. No significant differences in the distribution of comorbidities or the underlying pathologies of CA/CS between survivors and non-survivors were found (Table 1). 81 (65%) of our patients received a coronary angiography and stenting. Survivors of cardiogenic shock were significantly younger (53.50 [17.3] years vs. 71.0 [16.0] years; p<0.001), and baseline lactate of all patients was 4.7 [7.1mmol/L]. In survivors, we found lower baseline lactate of 2.1mmol/L [4.6mmol/L] as compared to non-survivors with 5.4mmol/L [6.7mmol/L] (Table 1). CPR duration was not associated with the outcome in our collective (Table 1). The type of Impella device (Impella 2.5, n = 91; Impella CP, n = 31; Impella 3.5, n = 3) was also not associated with mortality which was high (Impella 2.5, 84%; Impella CP, 79%; Impella 3.5, 100%; p = 0.59) in all devices.
The overall hospital mortality was high, with 81%. In the sub-group analysis of patients with previous CPR and acute myocardial infarction (AMI) as underlying pathology, the mortality rates were 87% and 82%. None of the concomitant diseases was associated with this endpoint. In univariable logistic regression previous CPR (OR 4.05 95%CI 1.59–10.35; p<0.003), age (OR 1.11 95%CI 1.06–1.16; p<0.001) and lactate (OR 1.26 95%CI 1.08–1.48; p = 0.004) were the only parameters associated with hospital mortality (Table 2). However, after performing the multivariable logistic regression analyses, only age (aOR 1.13 95%CI 1.06–1.20; p<0.001) and lactate (aOR 1.23 95%CI 1.004–1.516; p = 0.046) remained as indicators associated with hospital fatality events (Table 3).
Both age (AUC 0.80 95%CI 0.72–0.86) and lactate (AUC 0.73 95%CI 0.64–0.80) had high discrimination accuracy, the optimal cut-offs were >66 years and >3.3 mmol/L, respectively. Patients above 66 years (n = 72; 94% vs. 62%; p<0.001; Fig 1) and patients with an initial lactate concentration >3.3mmol/L (n = 82; 92% vs. 61%; p<0.001; Fig 1) evidenced significantly higher hospital mortality.
Scatter plot of both in hospital survivors (blue) and deceased patients (red) in relation to age and lactate levels. The raw data is accessible in the supporting information (S1 Table).
The patients were retrospectively stratified into three risk groups: Patients aged ≤66 years and lactate ≤3.3mmol (low-risk; n = 22); patients aged >66 years or lactate >3.3mmol/L (medium-risk; n = 52); and patients both aged >66 years and lactate >3.3mmol/L (high-risk, n = 51). The risk of death increased from 41% in the low-risk group to 79% in the medium-risk group and 100% in the high-risk group (Figs 2 and 3a; p<0.001). The predictive abilities of this model were high (AUC 0.84 95% 0.77–0.92).
Patients aged ≤66 years and lactate ≤3.3mmol (low-risk; n = 22); patients aged >66 years or lactate >3.3mmol/L (medium-risk; n = 52); and patients both aged >66 years or lactate >3.3mmol/L (high-risk, n = 51). The raw data is accessible in the supporting information (S1 Table).
Hospital survival rates in different sub-groups of CA/CS: a) the total cohort, b) patients with previous successful cardiopulmonary resuscitation (previous CPR) and c) acute myocardial infarction (AMI). The raw data is accessible in the supporting information (S1 Table).
The sensitivity analysis in patients with previous CPR revealed a high predictive ability (AUC 0.88 95%CI 0.79–0.96). In patients with previous CPR, the risk of death increased from 36% in the low-risk group to 79% in the medium-risk group and 100% in the high-risk group (Fig 3b; p<0.001). Also, in the patients with an AMI as primary underlying etiology, the model performed well (AUC 0.85 95%CI 0.77–0.93). In the patients with an AMI as primary underlying etiology, the risk of death increased from 33% in the low-risk group to 84% in the medium-risk group and 100% in the high-risk group (Fig 3c; p<0.001).
4.0 Discussion
Our study sought to analyze the outcomes, and the impact of baseline characteristics in real-world patients with CA/CS treated with an Impella assist device. The hospital mortality was high, while lactate and age were shown to be the only variables associated with hospital mortality. Indeed, other baseline variables, including concomitant diseases, were not associated with this endpoint. The death rate was 100% in the high-risk group across all sub-groups.
This is in accordance with previous trials. Age had a strong impact on the outcome in our collective, which was also found in previous studies [10]. Hyperlactatemia is commonly used in intensive care medicine as a marker for end-organ function [11,12]. Previous studies have demonstrated its predictive value in the prediction of patient mortality in the setting of septic shock [11]. Furthermore, a strong correlation of serum lactate and CS in the Impella collective of Rohm et al. was revealed [9]. However, the authors did not assess the impact of a previous successful CPR, which is a frequent etiology of cardiogenic shock in this population. Therefore, in our study, we included both successful CPR survivors and CS of other origins. We found a strong association between baseline lactate values as an indicator of end-organ function and hospital survival in our collective using multivariable analysis. In our analysis in sub-groups with previous CPR and acute myocardial infarction we were able to confirm these results. Based upon this we considered it feasible to combine patients with CA and CS for pragmatic and statistical reasons despite differing underlying pathologies. Other investigators presented similar results [9,12–15]. Indeed, survivors in our study also had a lower baseline-lactate value as suggested in the trials above or the Euroshock II study [10]. However, in our collective, 74.4% (93) of patients had a previous CPR. Of note, this percentage of patients was higher as compared to the Euroshock II trial, which also observed a significant influence of this parameter on fatal outcomes, again underlining the predictive value of lactate in severely ill CA/CS patients [10].
Additionally, only the Impella 2.5 pump was used in the Euroshock II trial, while in our cohort also the Impella 3.5 and CP were applied. We found no significant impact of Impella type on survival. This underlines the limitation of strategies restricted to provide hemodynamic stability through a high performing blood pump in CS.
Overall, in comparison to previous trials reporting a mortality rate of 64.2% in CS [10], in our real-world scenario, we observed a high mortality of 81%. However, as already discussed, previous CPR was frequent in our population.
Therefore, our findings might suggest that in a severely ill, real world collective of CA/CS the beneficial impact of an invasive assist device therapy might be even more limited as previously suggested. This underlines the importance of patient selection to provide the best medical care for specified populations. Indeed, Impella assist device therapy is limited due to the invasive nature of this procedure. Therefore, ethical consideration should be warranted when proceeding with this strategy in a high-risk population with a limited chance of survival. In our trial, by applying cut-off values for lactate and age, we were able to identify risk groups. Of note, this suggestive strategy could help to guide intensive care physician in daily clinical practice. We propose the application of an Impella guided strategy in younger patients (aged ≤66) and lower baseline lactate levels (lactate ≤3.3mmol/L) while this approach should be reconsidered when in older CS/CA patients high baseline lactate is revealed (aged >66 years and lactate >3.3mmol/L).
4.1 Conclusion
The mortality rate was high in this real-world collective of severely sick cardiogenic shock patients. Better patient selection is warranted to avoid unethical use of Impella. Age and lactate might help to guide decision making in clinical practice. Nevertheless, due to the heterogeneity of our real-world collective, these results must, however, be individually scrutinized in each patient and should not lead to an inadequate holdback of Impella therapy in selected patients.
4.2 Limitations
This study has several limitations due to its single-center and retrospective design with a small patient number. Additionally, we included patients with CA/CS that in 93 cases have had a CPR. The combination of these collectives could lead to an overestimated mortality due to the poor outcome in patients with CPR. However, this combination is common in a real-world setting, additionally we found similar results in our sub-group analysis with regard to selected pathologies.
References
- 1. Burzotta F, Trani C, Doshi SN, Townend J, van Geuns RJ, Hunziker P, et al. Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user group. Int J Cardiol. 2015;201:684–91. pmid:26363632
- 2. Chera HH, Nagar M, Chang NL, Morales-Mangual C, Dous G, Marmur JD, et al. Overview of Impella and mechanical devices in cardiogenic shock. Expert Rev Med Devices. 2018;15:293–299. pmid:29600725
- 3. Teuteberg JJ and Chou JC. Mechanical circulatory devices in acute heart failure. Crit Care Clin. 2014;30:585–606. pmid:24996610
- 4. Lemaire A, Anderson MB, Lee LY, Scholz P, Prendergast T, Goodman A, et al. The Impella device for acute mechanical circulatory support in patients in cardiogenic shock. Ann Thorac Surg. 2014;97:133–8. pmid:24090575
- 5. Lackermair K, Sattler S, Huber BC, Grabmaier U, Weckbach LT, Bauer A, et al. Retrospective analysis of circulatory support with the Impella CP(R) device in patients with therapy refractory cardiogenic shock. Int J Cardiol. 2016;219:200–3. pmid:27327507
- 6. Nalluri N, Patel N, Saouma S, Anugu VR, Anugula D, Asti D, et al. Utilization of the Impella for hemodynamic support during percutaneous intervention and cardiogenic shock: an insight. Expert Rev Med Devices. 2017;14:789–804. pmid:28862481
- 7. Abaunza M, Kabbani LS, Nypaver T, Greenbaum A, Balraj P, Qureshi S, et al. Incidence and prognosis of vascular complications after percutaneous placement of left ventricular assist device. J Vasc Surg. 2015;62:417–23. pmid:26054591
- 8. Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, et al. Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA. 2020. pmid:32040163
- 9. Rohm CL, Gadidov B, Leitson M, Ray HE and Prasad R. Predictors of Mortality and Outcomes of Acute Severe Cardiogenic Shock Treated with the Impella Device. Am J Cardiol. 2019;124:499–504. pmid:31262498
- 10. Lauten A, Engstrom AE, Jung C, Empen K, Erne P, Cook S, et al. Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry. Circ Heart Fail. 2013;6:23–30. pmid:23212552
- 11. Masyuk M, Wernly B, Lichtenauer M, Franz M, Kabisch B, Muessig JM, et al. Prognostic relevance of serum lactate kinetics in critically ill patients. Intensive Care Med. 2019;45:55–61. pmid:30478622
- 12. Lichtenauer M, Wernly B, Ohnewein B, Franz M, Kabisch B, Muessig J, et al. The Lactate/Albumin Ratio: A Valuable Tool for Risk Stratification in Septic Patients Admitted to ICU. Int J Mol Sci. 2017;18.
- 13. Ouweneel DM, Eriksen E, Sjauw KD, van Dongen IM, Hirsch A, Packer EJ, et al. Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction. J Am Coll Cardiol. 2017;69:278–287. pmid:27810347
- 14. Slottosch I, Liakopoulos O, Kuhn E, Scherner M, Deppe AC, Sabashnikov A, et al. Lactate and lactate clearance as valuable tool to evaluate ECMO therapy in cardiogenic shock. J Crit Care. 2017;42:35–41. pmid:28672145
- 15. Jung C, Bueter S, Wernly B, Masyuk M, Saeed D, Albert A, et al. Lactate Clearance Predicts Good Neurological Outcomes in Cardiac Arrest Patients Treated with Extracorporeal Cardiopulmonary Resuscitation. J Clin Med. 2019;8. pmid:30889788